Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director. Dr. Maymon-Pomeranchik, 43, is trained as a molecular and genetic researcher holding a PhD from the Hebrew University, and brings nearly 20 years of executive level experience in biotech sciences, with particular expertise in the global medical cannabis industry. Dr. Maymon-Pomeranchik also serves on the boards of several public companies.
Co-founder and CEO Eyal Barad commented "As a new Independent Director, Inbar undoubtedly brings significant added value to our company, given her extensive global executive experience in our industry, in leadership positions, as well as her deep scientific knowledge in technical analysis of new and innovative technologies. We look forward to working with Inbar towards expanding our technological capabilities laterally into new and emerging market opportunities."
Dr. Inbar Maymon-Pomeranchik noted "It is a great honor to join the Board of Directors of Cannabics Pharmaceuticals. Cannabics is a known leader in the development of anti-cancer medicines based on cannabinoid molecules, and I am excited to become part of the company's plan to enter FDA approval tracks for its growing pipeline of potential drug candidates. I look forward to working with the company Board to create value for our shareholders."
About Dr. Inbar Maymon Pomeranchik:
Dr. Maymon-Pomeranchik is the founder & CEO of AgChimedes Group Ltd., a company focused on the convergence of science, innovation and investment in the field of food security; she also founded BioDiligence, a biotech investment consultancy; Executive Director of Ananda Developments Pls (UK), an investment and operational firm that targets medicinal cannabis derivatives for research and development; a Director of NRGene (Israel), a company that develops and commercializes cutting-edge AI based genomic tools, and an Advisory Board member of Avida Global Ltd. (UK/Columbia), Avida is a leading licensed producer of pharmaceutical grade cannabis extract for scientific and medical use. Dr. Maymon-Pomeranchik holds a PhD in plants science and molecular biology from the Hebrew University (2008) and a Post Doctorate from the Weizmann Institute (2010).
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
For more information about Cannabics:
View original content to download multimedia:https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-announces-appointment-of-new-independent-board-member-301326964.html
SOURCE Cannabics Pharmaceuticals Inc.
Company Codes: OTC-PINK:CNBX, Bloomberg:8C8@GR, Bloomberg:CNBX@US, ISIN:US13764M1009, Munich:8C8, OTC-QB:CNBX, OtherOTC:CNBX, Stuttgart:8C8